Although breast cancer molecular subtypes have been extensively defined by means of gene expression profiling over the past decade, little is known, at the proteomic level, as to how signaling pathways are differentially activated and serve to control proliferation in different breast cancer subtypes. We used reverse-phase protein arrays to examine phosphorylation status of 100 proteins in a panel of 30 breast cancer cell lines and showed distinct pathway activation differences between different subtypes that are not obvious from previous gene expression studies. We also show that basal levels of phosphorylation of key signaling nodes may have diagnostic utility in predicting response to selective inhibitors of phosphatidylinositol 3-kinase and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase. Finally, we show that reverse-phase protein arrays allow the parallel analysis of multiple pharmacodynamic biomarkers of response to targeted kinase inhibitors and that inhibitors of epidermal growth factor receptor and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase result in compensatory up-regulation of the phosphatidylinositol 3-kinase/Akt signaling pathway.
Introduction
Breast cancer is a heterogeneous disease with distinct molecular subtypes that vary in prognosis and show differential response to both targeted and chemotherapeutic agents (1, 2) . Over the past 30 years, the clinical management of breast cancer has become increasingly personalized with routine use of diagnostic tests to determine whether patients should receive targeted therapies, such as Tamoxifen for hormone receptor -positive disease (3) and Trastuzumab for HER2-positive disease (4) . Several trends suggest that this personalization is likely to continue and, indeed, perhaps result in even finer stratification of patients in the future. First, an explosion of gene expression profiling and classification studies has revealed additional complexity and substructure within the overall framework of breast cancer (2) . That is, whereas most expression profiling studies recognize at least three main subtypes, termed luminal, basal-like, and HER2 amplified, certain studies have uncovered gene sets that refine the classification breast of tumors into as many as six distinct subtypes (5) . Assuming that these subtypes harbor distinct pathological alterations and mechanisms of signaling pathway dysregulation, it seems likely that novel therapeutics targeting particular signaling pathways may have activity in specific subsets of patients. Second, there are currently over 1,400 phase II or phase III clinical trials under way in breast cancer, 3 a number of which examine the role of new targeted therapies in disease management, suggesting an increasing necessity of additional diagnostic strategies to target novel agents to appropriate patient populations.
Although gene expression studies have been very fruitful at identifying breast cancer subtypes and predicting disease recurrence (6) , there is nevertheless a need for complementary diagnostic technologies that can assess the overall status of signaling networks and provide information that is not apparent at the transcriptome level. The reasons for this are severalfold. First, transcriptional changes in gene expression are a distal output of signal transduction pathways (7) and may not provide a real-time reflection of the activation state of a given pathway. Second, the high dimensionality of gene expression data creates a false discovery problem that makes it difficult to relate specific transcriptional changes to the activation of a particular pathway (8) . Thirdly, in past studies where gene and protein expression were directly compared, a majority of the comparisons showed poor concordance between gene and protein expression (9 -12) ; thus, it is not a certainty that gene expression can predict protein expression levels. Finally, the functional components of signal transduction pathways at a cellular phenotypic level are posttranslational in nature and involve a complex interplay between phosphorylation by kinases, dephosphorylation by phosphatases, and protein degradation through ubiquitination. These rapid and dynamic changes in pathway status are inherently difficult to capture in real time through gene expression surrogates. Also, because many inhibitors currently in development are specific kinase inhibitors that impair components of these signal transduction cascades, readouts of pathway activation states would be of great utility to both the drug and companion diagnostic development process. For instance, assays for pretreatment phosphorylation levels could be used to determine whether a signaling pathway was activated in a patient's tumor and, hence, whether the patient might benefit from a specific inhibitor that targeted a key node in that pathway (i.e., predictive biomarkers; ref. 13 ). In addition, assays for phosphorylation status of kinase substrates that could be conducted on small amounts of patient material pretreatment and posttreatment could serve as reliable indicators that a drug was effectively modulating target activity at a particular dose and schedule (i.e., pharmacodynamic biomarkers).
In light of these considerations, we have investigated the use of reverse-phase protein arrays (RPPA) to determine the signaling pathway status in a large panel of breast cancer cell lines that have previously been characterized in detail at the gene expression and copy number level and shown to reflect many of the genomic alterations commonly found in breast tumors (13, 14) . Previous studies using RPPAs in cell lines have focused on panels of cell lines derived from multiple tissue types (15, 16) and have not sought to address signaling network heterogeneity within the context of a single tumor type. The overarching questions we sought to address were, first, whether breast cancer molecular subtypes have distinct patterns of pathway activation that can be discerned through this type of network analysis and, second, whether high levels of activation of a particular pathway can predict response to selective inhibitors of key nodes of that pathway. RPPAs were chosen for this study because they offer the potential to profile potentially hundreds of phosphorylation events in very small quantities of tumor materials, such as those that might be obtained from laser capture microdissection from a biopsy (17, 18) . The basis of the technology is to immobilize small amounts of lysate from a cell line or tumor sample in serial dilution on a microarray slide. Multiple samples are, thus, arrayed on a slide and can be probed with antibodies that detect a particular phosphorylated epitope (17) . Using this technology, we profiled 100 key signaling nodes representing a number of pathways known to be dysregulated in cancer across the panel of 30 cell lines. The key findings of this study are that differentially phosphorylated proteins cannot only classify cell lines fairly accurately into molecular subtypes but also provide an indication that basal-like cell line models are characterized by high levels of SRC family and epidermal growth factor receptor (EGFR)/RAS/extracellular signalregulated kinase (ERK) signaling, whereas luminal cell lines show high levels of activation of phosphatidylinositol 3-kinase (PI3K)/mTOR pathway components. In addition, we find that basal levels of signaling through the mitogenactivated protein kinase/ERK kinase (MEK)/ERK and PI3K/AKT pathway are correlated with in vitro response to inhibitors of MEK kinase and PI3K, respectively. Finally, we show that targeted inhibitors of MEK, PI3K, and EGFR have measurable effects on key signaling pathway components, suggesting that RPPAs could play a role in optimizing dose and schedule for such agents in early stage clinical trials.
Materials and Methods
Cell Lines Breast cancer cell lines AU565 BT-474, BT-549, BT-483, CAMA-1, HCC1143, HCC1419, HCC1428, HCC1500, HCC1569, HCC1937, HCC1954, Hs578T, KPL-1, MCF-7, MDA-MB-175-VII, MDA-MB-231, MDA-MB-361, MDA-MB-435S, MDA-MB-436, MDA-MB-453, MDA-MB-468, and ZR-75-1 were obtained from American Type Culture Collection. The cell lines CAL-120, CAL-51, CAL-85-1, EFM-19, EFM-192A, and EVSA-T were obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH. All cell lines were maintained in RPMI 1640 or DMEM supplemented with 10% fetal bovine serum (Sigma), nonessential amino acids and 2 mmol/L L-glutamine. In vitro cell viability studies were conducted as described previously (13) . Kinase inhibitors used in this study include the MEK1/2 inhibitor PD0325901 (Pfizer; ref. 19) , the PI3K/mTOR inhibitors PI-103 (20) and GDC-0941 (21) , and the EGFR inhibitor Erlotinib (Tarceva, Genentech). PD0325901 is a selective MEK inhibitor that acts through a novel noncompetitive allosteric mechanism of action involving binding to a site adjacent to the ATPbinding site and locking the kinase in a closed and catalytically inactive conformation (22) . PI103 is a potent and selective PI3K inhibitor with low IC 50 values against recombinant PI3K isoforms p110a, p110h, p110y, p110g, mTOR, and DNA-PK (20) . GDC-0941 is a potent and selective inhibitor of all four isoforms of the catalytic subunit of PI3K that is currently in phase I clinical trials (21) . Erlotinib (Tarceva) is a small molecule inhibitor of EGFR that is approved for treatment of advanced nonsmall cell lung cancer and first line metastatic pancreatic cancer (23) .
Western Blot Analyses For analyses of basal levels of phosphorylated Akt, 40,000 cells per well were plated in six-well plates in media containing 10% fetal bovine serum and allowed to grow for 48 h or until cells reached 60% to 80% confluence. Cells were washed with cold PBS and processed directly in the plate. DNase lysis buffer [80 AL; 10 mmol/L Tris-HCl (pH 8), 3 mmol/L MgCl 2 , 10 mmol/L NaCl, 1% Triton X-100 supplemented with protease inhibitor cocktail (Sigma P 8342), phosphatase inhibitor I cocktail (Sigma P 2850), phosphatase inhibitor II cocktail (Sigma P 5726), phenylmethylsulfonyl fluoride, and DNase (Sigma D7291)] was added to each well and then incubated, shaking at 37jC for 10 min. NuPAGE LDS 4Â sample buffer (Invitrogen) and NuPAGE 10Â sample reducing agent (Invitrogen) were added, and the samples were heated to 70jC for 10 min and then loaded directly into NuPAGE 4% to 12% Bis-Tris precast gel (Invitrogen). Primary blotting antibodies used were total AKT and pAKT (S 473 ; Cell Signaling Technology). Secondary blotting antibodies used were polyclonal goat anti-mouse IgG horseradish peroxidase and polyclonal goat anti-rabbit IgG horseradish peroxidase (both from Dako, Glostrup, Denmark or Cell Signaling Technology).
PTEN Small Interfering RNA Experiments OnTARGET Plus small interfering RNA (siRNA) specific to human PTEN (Dharmacon) or a control siRNA that does not target any sequence in the human genome (nontarget control, Dharmacon) were used in transient transfection experiments. Optimal siRNA duplex and lipid concentrations were determined for each cell line. Nontargeted siRNA nucleotides (Dharmacon) were used as nonspecific controls in all experiments. Transfection efficiency of PTEN siRNA was evaluated by Western blot for human PTEN. MDA-MB231 cells were plated at 6,000 cells per well in a 96-well plate with 0.125 AL of Lipofectamine RNAiMAX (Invitrogen) and 50 nmol/L of siRNA per well. Cells were incubated for 3 d in siRNA then harvested and processed for RPA analysis, as described below.
Reverse-Phase Protein Arrays Cells were grown in standard media and 10% fetal bovine serum until they reached 60% to 80% confluence and then lysed directly in plates in buffer consisting of a 2.5% solution of 2-mercaptoethanol in loading buffer/ T-PER plus phosphatase and protease inhibitors. For pharmacodynamic studies, cells were plated in six-well plates and allowed to adhere overnight and either lysed immediately or after 6 h of incubation in the presence of 1 Amol/L of each compound. Samples were shipped on dry ice to Theranostics Health, LLC for the reverse-phase protein array (RPPA) analysis. All samples were diluted to a final concentration of 0.5 mg/mL and then 30 AL of each sample, arrayed in a series of six fold dilutions, was printed in duplicate on slides. Lysates derived from HeLa cells or HeLa cells treated with pervanadate were also printed on each slide as low and high phosphorylation controls, respectively. The slides were then subjected to immunostaining with a panel of 100 antibodies primarily directed against specific phosphorylated or cleaved proteins. Each of these antibodies had previously undergone extensive validation for both phosphorylation and protein specificity using single band detection at the appropriate MW by Western Blotting. The specific protein and phosphoprotein assays are listed in Supplementary Table S1 . 4 To allow normalization of total protein on printed arrays, one to two slides in each print run were stained with Sypro Ruby protein blot stain (Invitrogen) and the value of these stained arrays used for normalization of all end point values. The intensity value for each end point was determined by identifying spots for each duplicate dilution curve for each sample that were within the linear dynamic range of the staining after background subtraction with each spot (within slide local background and also against a slide stained with secondary antibody only). Single intensity values were obtained by multiplying each spot in the linear range by its dilution factor and averaging candidate linear points. Finally, each value was normalized relative to the total protein intensity value for that sample derived from the Sypro Ruby -stained slide.
Statistical Analyses Data analysis was done with Partek Genomics Suite software version 6.3 (Partek, Inc.). RPPA data was preprocessed by log2 transformation and further linear scaling (z-score conversion) to ensure data normality and linearity. The log-transformed data were used for principle component analysis (PCA) and other statistical analyses, and the z-scores were used in hierarchical cluster analysis. For unsupervised hierarchical clustering analysis, a max/ min ratio was calculated for each end point based on the highest and lowest intensity samples. The top 50 assays based on max/min ratio were log transformed and median centered and then subjected to average linkage clustering using a correlation similarity metric. Analysis and visualization of data were conducted using cluster and treeview software (24) .
PCA was used to reduce the dimensionality of the data and detect the dominant sources of variation in the data. For the identification of differentially expressed or phosphorylated markers we, used a one-way ANOVA with a 0.05 P-value threshold. To further validate the selected markers from ANOVA, unsupervised hierarchical cluster analysis was done to test the clear segregation of different molecular subtypes. Hierarchical cluster analysis was done using distance matrix of Pearson correlation with average linkage method and PCA with correlation dispersion matrix and normalized eigenvector scaling. A post hoc analysis of ANOVA involving pairwise comparison was also done to select markers that showed statistically significant phosphorylation differences between the subtypes. Volcano plots were used to view markers that not only satisfied the statistical cutoff but also showed biological significance based on fold change (i.e., 2-fold).
To detect association between compound sensitivity and phosphorylation of particular end points, we first log transformed the in vitro EC 50 values for each compound (Supplementary Table S1 ) 4 and then used Pearson correlation and analysis of covariance to identify statistically significant correlations between EC 50 values and protein intensities.
Results

Technical Validation of Arrays
We profiled protein lysates from 30 breast cancer cell lines with a panel of 100 antibodies recognizing primarily phosphorylated epitopes. Identities of the phosphorylated and total proteins profiled, as well as normalized signal intensities for each of these antibody end points in all cell lines are provided in Supplementary Table S1 . 4 Also shown is the molecular subtype for each cell line, determined as previously described (13), as well as notable genetic alterations in each cell line (e.g., KRAS, BRAF, PTEN, PIK3CA status).
We first sought to determine reproducibility of the data by analyzing independently derived lysates (passage 1 versus passage 2) from MDA-MB-231 cells and found significant correlation between the 100 end points from the independent samples (Pearson correlation, r = 0.94; Supplementary Fig. S1 ). 4 Next, we sought to compare results from the RPPA analysis with independent data derived from the same cell lines using different methods. First, we compared protein intensity for EGFR determined by RPPA with mRNA levels determined on Affymetrix Human Genome U133 Plus 2.0 arrays and found these measurements to be significantly correlated (Pearson correlation, r = 0.80; Supplementary Fig. S2A ). 4 Next, we compared phosphorylated PTEN (S 380 ) levels with PTEN levels determined from independent lysates derived from the same cell lines and found that cell lines determined to be PTEN null (no protein band) by Western blotting were uniformly low for the pPTEN (S 380 ) RPPA end point. We also found good concordance between phosphorylation of AKT at S 473 and T 308 determined by Western blot and (25) and whose growth regulatory properties are primarily mediated via its lipid phosphatase activity, which specifically reduces the cellular levels of phosphatidylinositol 3,4,5-trisphosphate and, thus, serves to blunt signaling through the PI3K/AKT pathway when intact (26) . We confirmed PTEN knockdown at the protein level by Western blot (data not shown) and then used a t-statistic to identify phosphorylated end points that differed significantly between control siRNA-treated cells and PTEN siRNA-treated cells (using a cutoff of P < 0.05; Fig. 1A ). Of note, we found that a number of key regulatory phosphorylation sites in the PI3K/AKT pathway are altered upon PTEN knockdown, including sites on mTOR, LKB1, p70S6K, and 4EBP1 (Fig. 1B) . Interestingly, we found a decrease in the phosphorylation of the T 37 and T 46 sites on 4EBP1 and a concomitant increase in the T 70 site. It has been shown previously that 4EBP1 phosphorylation by mTOR on T 37 and T 46 is a priming event for subsequent phosphorylation of the carboxy-terminal (S 65 and S 70 ; ref. 27) , and that dual phosphorylation of S 65 and S 70 is required to abrogate binding of 4EBP1 to the translation factor eIF4E and, thus, stimulate initiation of translation (28) . The reasons for differential behavior of these phosphorylated sites on 4EBP1 are unclear but may reflect a regulatory feedback loop whereby the priming sites are dephosphorylated in response to the activation of the protein. Together, these results suggest that perturbation of a key signaling node can have consequences on pathway activation that can be assessed through multiplexed readouts on RPPAs.
Breast Cancer Molecular Subtypes Intensive efforts over the past decade have revealed that breast cancers can be stratified into molecular subtypes with distinct molecular genetic alterations and prognostic outcomes using gene expression profiling (2) . Luminal breast cancers are typically estrogen receptor positive and characterized by a coordinate expression of a number of epithelial specific genes, a relatively good prognosis, and good response rates to targeted hormonal therapies (3). HER2-positive breast cancers are characterized by the high-level gene amplification of HER2 oncogene, relatively poor prognosis if untreated, and significant clinical benefit from the HER2-targeting monoclonal antibody Trastuzumab (Herceptin, Genentech; ref. 29) . Basal-like breast cancers typically lack expression of HER2, ER, and progesterone receptor and, hence, overlap with tumors immunohistochemically defined as ''triple negative'' tumors (30) . Basal-like breast cancers have a poor prognosis and currently have not been shown to respond to any targeted therapy and, thus, represent a particularly pressing unmet medical need (31) . To date, little effort has been focused on identifying signaling pathway activation differences that characterize the distinct molecular subtypes at the proteomic level, although such efforts are currently under way using RPPA technology along with human tumor specimens (31) . Such efforts could have implications both for the development of novel-targeted agents that may show efficacy in particular subtypes, as well as more personalized administration of emerging targeted therapies. The cell lines used in the study have previously been classified into the three major molecular subtypes using a combination of gene expression data and HER2 status (13) . Briefly, cell lines were assigned to luminal or basal-like classes using gene expression data, and then cell HER2 amplification status was assigned by means of quantitative reverse transcription -PCR on genomic DNA to identify cell lines with greater than four copies of the HER2 locus. Here, we sought to determine whether phosphorylated protein status from RPPA arrays could provide insights into the signaling pathways that are active in the different subtypes. We first used PCA to reduce dimensionality of the data and find patterns that might be related to the differential activity of signaling pathways in particular subtypes of breast cancer. The resulting PCA plot ( Fig. 2A) shows that the global proteomic signature determined by this method largely separates basal-like cell lines from HER2 amplified and luminal cell lines along the second principal component. Also, with the exception of the HER2-amplified line BT474, the majority of the luminal lines are separated from the HER2 lines. This analysis suggests that the phosphorylated protein end points in this analysis are significantly correlated because the first three principal components can account for 61% of the variance in the data and also that distinct pathways may be activated in the different subtypes.
To explore in more detail which particular end points or signaling modules are predominantly active in a given subtype, we constructed a one way ANOVA model derived from pairwise comparisons of the different subtypes and then used the top end points from that model to perform unsupervised hierarchical clustering on the cell lines (Fig. 2B ). This analysis recapitulated the clustering results derived from gene expression analysis because it partitioned the cell lines into distinct clusters with luminal cell lines (based on gene expression) clearly separated from basal-like lines. To a lesser extent, the HER2-amplified cell lines formed a distinct grouping, although several of the HER2-amplified lines were found to cluster with luminal cell lines in this analysis. This finding is consistent with gene expression clustering of breast cancer cell lines because such studies report that breast cancer cell lines resolve into only two main clusters regarded as luminal and basal-like and do not reveal a separate HER2-amplified subtype (14) . Moreover, this analysis suggests specific pathway activation events may (Fig. 2B and  C) . In particular, basal-like lines were found to be distinct from luminal and Her2-amplified lines in having low levels of pPTEN and high levels of total EGFR, Pyk2 (Y 402 ), and PKC-a (S 567 ). HER2-amplified cell lines were distinct from the other subtypes in having high levels of pERBB3, pFAK, and pEGFR (Y 1173 ), and luminal cell lines were distinct in having higher levels of phosphorylation of pp70S6K (S 371 ) and pA-RAF (S 299 ). We also used volcano plots to compare the fold change in intensity with the statistical significance level for luminal-basal markers identified from ANOVA analysis ( Supplementary Fig. S3) . 4 This analysis suggested that high levels of EGFR and phosphorylation of Pyk2 and PKC-a are characteristics of basal-like cell lines, whereas phosphorylation of A-RAF, p70S6K, and PDK1 are characteristic of luminal cell lines. In a parallel approach, we ranked the end points based on the level of differential phosphorylation (as described in Materials and Methods) across the cell line panel and then used the top 50 differentially phosphorylated end points in hierarchical clustering analysis (Fig. 3) . This analysis again showed that differential phosphorylation of these signaling pathway proteins organizes the cell lines into two overall clusters that are quite similar to those derived from gene expression analyses. In addition, this analysis revealed patterns of pathway activation that are not obvious from published gene expression analyses. In particular, basal-like cell lines were found to have high levels of phosphorylation of nonreceptor tyrosine kinases, such as c-Abl and Pyk2, and in addition showed generally high levels of Erk1/2 phosphorylation and high total EGFR expression. In contrast, HER2-amplified cell lines were found to have high levels of phosphorylation of components of HER receptor signaling (e.g., SHC, ERBB3, EGFR), as well as other receptor tyrosine kinases (e.g., c-MET). Finally, luminal cell lines that do not have apparent amplification of HER2 showed generally higher levels of activation of downstream signaling pathway components in the Akt/mTOR pathway (e.g., p70S6K). Predicting Sensitivity toTargeted Therapeutics A potentially important application of RPPA technology is the more personalized administration of targeted therapies based on the signaling status of a given patient's tumor. The assumption is that if a patient's tumor is addicted to the continued activation of a particular pathway for continued growth and survival (32) , then phosphorylation at key nodes in that pathway may serve as hallmarks, indicating the presence of an activated pathway and the potential for therapeutic intervention with inhibitors targeting that pathway. To address the preclinical feasibility of such an approach, we sought to determine whether the pretreatment levels of specific phosphorylated end points showed correlation with in vitro response to potent and selective PI3K and MEK inhibitors. Genetic and biochemical analyses of MEK function have suggested that MEK activity is necessary for the transforming and proliferative effects of this pathway, suggesting that therapeutics that completely inhibit MEK function may have utility in the treatment of cancers driven by activation of the RAS/RAF axis (33) . Similarly, PI3K is a key transducer of growth factor signals from receptor tyrosine kinases, as well as a frequently mutated oncogene, suggesting that PI3K inhibitors might have beneficial effects in treating cancers driven by pathologic alterations of this pathway (34) . As described in Materials and Methods, we used Pearson correlation and an analysis of covariance model (ANCOVA) to identify the phosphorylated proteins that showed the highest correlation with drug sensitivity for these agents. For the MEK inhibitor (Fig. 4) , we found significant correlation (P < 0.05) between sensitivity (i.e., low EC 50 ) and expression of total EGFR and phosphorylated ERK1/2 (the direct targets of MEK phosphorylation), suggesting that constitutive signaling through the EGFR/RAS/MEK/ERK axis may constitute a positive predictive factor for MEK inhibition (Table 1 ; Fig. 4 ). We also note that phosphorylation of the nonreceptor tyrosine kinases Pyk2 and Abl, as well as PKC-a, were positively correlated with response to the MEK inhibitor. Conversely, phosphorylation of components of Akt and mTOR signaling, such as PDK1 and p70S6K, was negatively associated with response to the MEK inhibitor (Table 1 ). In contrast, we found that sensitivity to the PI3K/ mTor inhibitor PI-103 was significantly correlated with elevated phosphorylation at key nodes in the PI3K/Akt/ mTOR pathway, including pAkt (T 308 and S 473 ), PRAS40 (T 246 ), and FKHR (T 24 ; Table 1 ), suggesting that high levels of signaling through the pathway may be indicative of pathway addiction and predictive of response to a targeted PI3K inhibitor.
Pharmacodynamic Effects of Targeted Kinase Inhibitors
We determined the quantitative in vitro pharmacodynamic effects of small molecule kinase inhibitors of Figure 4 . Sensitivity to a MEK inhibitor is associated with high levels of EGFR/Pyk2 and Erk1/2 signaling. Logtransformed EC 50 data for the MEK inhibitor and selected end points that showed significant association with MEK sensitivity based on Pearson correlation were used to perform unsupervised hierarchical clustering analysis. Sensitivity to the MEK inhibitor (green ; low EC 50 ) is associated with high levels of EGFR expression and high levels of phosphorylation of Erk1/2 and Pyk2 (red).
MEK1/2, PI3K, and EGFR on a subset of 24 signaling pathway components (Supplementary Table S2) . 4 We evaluated phosphorylation of all 24 end points pretreatment and posttreatment (6-hour treatment) with each compound in the cell lines CAL85-1 and MDAMB231. CAL85-1 is a basal-like breast cancer cell line with submicromolar in vitro EC 50 sensitivity to all three compounds (0.33 Amol/L for GDC0941, 0.11 Amol/L for PD0325901, and 0.23 Amol/L for Erlotinib). MDAMB231 is a KRAS/BRAF mutant basal-like breast cancer cell line with submicromolar in vitro EC 50 sensitivity to GDC0941 and PD0325901 (0.82 and 0.31 Amol/L, respectively), which is relatively insensitive to Erlotinib (EC 50 4.84 Amol/L). Figure 5 shows the results for the protein end points that showed at least a 2-fold change between the 0 and 6 hour time points for at least one agent in each cell line. Treatment with the PI3K inhibitor GDC-0941 resulted in coordinate down-regulation of multiple components of the PI3K/ mTOR axis in both cell lines, including pAkt (S 473 ), pp70S6K (T 389 ), 4EBP1, and pS6 ribosomal protein. In contrast, treatment with the MEK inhibitor resulted in decreased levels of pErk1/2 and, somewhat surprisingly, up-regulation of key nodes in the PI3K pathway, such as pAkt and pS6. This finding suggests the existence of a feedback loop whereby inhibition of the MEK/ERK axis causes up-regulation of signaling in the PI3K/AKT pathway. Finally, treatment with the EGFR inhibitor had little or no effect on downstream pathway components, such as pErk1/2, in the unresponsive KRAS mutant cell line MDAMB231 but did dramatically reduce pErk1/2 levels in the sensitive cell line CAL85-1. In addition, Erlotinib treatment also caused up-regulation of pAkt (S 473 ) and pS6 in a manner similar to MEK inhibition in this cell line.
Discussion
We show here that signaling pathway network analysis based on RPPAs can efficiently classify breast cancer cell lines into molecular subtype in a manner similar to gene expression data. Moreover, this type of network analysis gives additional information as to the key pathways that may be dysregulated in particular disease subtypes and individual cancers and also may be useful in monitoring pathway modulation in response to targeted therapies and, thus, determining optimal biological dosing in clinical trials.
The findings presented here are in broad agreement with previous studies using RPPA analysis on laser capture microdissected cells obtained from surgically resected primary breast tumor materials from 25 patients that showed that tumors could be broadly clustered into subgroups based on EGFR signaling, AKT/mTOR activation, c-Kit/Abl activation, and Erk pathway activation (35) . In addition, our studies extend these findings by showing that activation of these pathway modules seems to occur in a subtype-specific manner and can provide the basis for therapeutic intervention. In particular, we found that cell lines defined as basal-like have high levels of EGFR, activated ERK1/2, and phosphorylation of SRC-activated effector kinases, such as c-Abl and Pyk2. This is intriguing because basal-like cell lines have been shown to be a highly invasive, mesenchymal subtype with high metastatic potential (14, 36) . Indeed, previous studies in a limited number of cell lines have shown that c-Abl acts downstream of EGFR and Src and serves to promote invasion of aggressive basal-like cell lines (37) . In addition, studies have shown that coexpression of c-Src and EGFR is required to trigger an oncogenic signaling program that leads to the transformation of mammary epithelial cells (38) . Our results suggest that this constellation of events may occur endogenously specifically in basal-like breast cancer. Consistent with this notion, others have shown that the Src inhibitor dasatinib specifically has antitumor activity in basal-like cell lines (39, 40) , and we show here that activity as selective inhibitor of the downstream MEK kinase is correlated with the up-regulation of the c-Src axis and constitutive signaling through ERK1/2. Conversely, we show that luminal cell lines have relatively low levels of activation of the EGFR/ERK/c-SRC axis but, in contrast, have elevated activation of downstream components of PI3K/mTOR signaling, such as PDK1 and p70S6 kinase. A hypothesis emerging from this finding would be that MEK inhibition would have little effect in luminal tumors but that a selective inhibitor of PI3K and mTOR might serve to inhibit tumor growth in these cancers and that targeted combination therapy could provide a powerful therapeutic candidate for these tumors. Consistent with this, we find that high levels of phosphorylation of key members of the PI3K/mTOR pathways are among the top predictors of PI-103 sensitivity in our unbiased analysis. An important caveat is that cell lines grown in two-dimensional culture in the presence of full serum are unlikely to fully recapitulate and mimic growth factor signaling in three-dimensional tumors but the observation that high levels of signaling through oncogenic pathways predicts in vitro response to targeted agents of these pathway points to the utility of cell line models to generate preclinical hypotheses that can be tested in the clinical setting. Our studies also highlight the potential utility of RPPAs in confirming pathway modulation upon therapeutic intervention and applications in examining pharmacodynamic biomarkers of drug response. Previous studies have shown that RPPAs could be used to monitor in vitro and in vivo pharmacodynamic response to the Akt inhibitor perifosine and that this inhibitor selectively inhibited the PI3K/AKT axis (41) . We have shown here that an inhibitor of all isoforms of the class I catalytic subunit of PI3K, GDC-0941, results in potent and selective inhibition of multiple nodes in the PI3K/Akt pathway and, thus, that RPPA arrays might have utility monitoring surrogate markers of compound activity. Conversely, we show that a selective MEK inhibitor results in potent down-regulation of pErk1/2 and actually increases signaling through the PI3K/Akt axis. This result highlights the fact that signaling pathways are dynamically linked networks and that perturbations in one pathway may have unforeseen consequences on interacting pathways that may affect response to therapeutic agents (42) . Ideally, monitoring pathway status in patients undergoing therapy could, thus, form the basis for subsequent intervention or even rational combination of agents based on the particular behavior of an individual's cancer. We also observed that pathway modulation could be associated with efficacy in two EGFR inhibitor-treated cell lines because an erlotinib responsive cell line showed dramatic reduction in pErk1/2 whereas a KRAS mutant, nonresponsive cell line failed to show down-regulation of pErk1/2. This is intriguing because clinical studies in patients with metastatic nonsmall cell lung cancer have suggested that KRAS mutations are associated with lack of clinical benefit from erlotinib (43, 44) . A simple model for these observations is that activation of KRAS through oncogenic mutation results in constitutive signaling through Erk1/2, which is not blocked by inhibition at the level of the receptor. This result again highlights the potential benefits of using RPPAs to examine pathway behavior in response to therapeutic agents to make an early decision as to whether a particular patient will benefit from a given treatment.
Another appealing facet of using RPPA technology for molecular diagnostic applications suggested by our results is the ability to capture overall pathway activation that can arise from multiple independent activating inputs. For instance, activating mutations in p110a, loss of PTEN, and amplification of HER2 all occur in breast cancer (45 -47) and all result in constitutive signaling through the PI3K/ AKT/mTOR axis. In the absence of a global readout of pathway activation, multiple independent assays (e.g., PIK3CA mutations, PTEN IHC, HER2 FISH or IHC) would need to be run on clinical specimens and might still not capture novel inputs into the pathway. The multiplex nature of RPPAs allows key nodes of the pathway to be examined in parallel and would greatly streamline diagnostic analyses of patient material. Of course, a number of hurdles need to be overcome before this method can be successfully used in clinical practice. Chief among these hurdles is the fact that tumor biopsies are most commonly fixed in formalin, a process which results in extensive cross-linking of proteins and alters immunoreactivity. Successful incorporation of RPPAs for analysis of clinical samples will require either collection of flash frozen biopsy material or the development of novel fixation conditions that leave phosphoepitopes intact. Efforts directed at understanding preanalytic fluctuations of phosphoproteins during tissue procurement (48) and the development of novel fixatives have been reported (49) and should portend a bright future for the use of RPPAs in the clinical setting.
Taken together, our findings suggest that proteomic analysis of cell line models of breast cancer can reveal pathway activation portraits that are not apparent by other means and have the potential to form the basis for personalized administration of targeted agents.
